Libtayo (Cemiplimab)
cemiplimab 350 mg/7 mL injection, 7 mL vial · INJECTION · PBS code 13152F
AUTHORITY_REQUIREDWhat it costs
AU$7290 PBS-determined price per pack
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2022-11-01.
- • Repeats: 2.
- • PBS program: IP.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC)
Initial treatment covering the first 3 treatment cycles
The condition must be unsuitable for each of: (i) curative surgical resection, (ii) curative radiotherapy; AND
Patient must have had a WHO performance status of 0 or 1; AND
The treatment must be the sole PBS-subsidised therapy for this condition.
Sponsor: MEDISON PHARMA AUSTRALIA PTY LIMITED ABN 19 659 723 403
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.